158 related articles for article (PubMed ID: 21656328)
1. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
Niwińska A; Olszewski W; Murawska M; Pogoda K
J Neurooncol; 2011 Dec; 105(3):547-53. PubMed ID: 21656328
[TBL] [Abstract][Full Text] [Related]
2. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
4. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
6. Brain metastases free survival differs between breast cancer subtypes.
Berghoff A; Bago-Horvath Z; De Vries C; Dubsky P; Pluschnig U; Rudas M; Rottenfusser A; Knauer M; Eiter H; Fitzal F; Dieckmann K; Mader RM; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
Br J Cancer; 2012 Jan; 106(3):440-6. PubMed ID: 22233926
[TBL] [Abstract][Full Text] [Related]
7. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
8. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
10. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
11. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
12. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
Sihto H; Lundin J; Lundin M; Lehtimäki T; Ristimäki A; Holli K; Sailas L; Kataja V; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
Breast Cancer Res; 2011 Sep; 13(5):R87. PubMed ID: 21914172
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.
Bryan BB; Schnitt SJ; Collins LC
Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377
[TBL] [Abstract][Full Text] [Related]
16. [Basal-like breast cancers: clinicopathological features and outcome].
De Brot M; Soares FA; Stiepcich MM; Cúrcio VS; Gobbi H
Rev Assoc Med Bras (1992); 2009; 55(5):529-34. PubMed ID: 19918651
[TBL] [Abstract][Full Text] [Related]
17. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
20. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.
Sasa M; Bando Y; Takahashi M; Hirose T; Nagao T
J Surg Oncol; 2008 Jan; 97(1):30-4. PubMed ID: 17929254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
